DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for hypertrophic cardiomyopathy 4 — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypertrophic cardiomyopathy 4 maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypertrophic cardiomyopathy 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
LIM domain binding 3 (LDB3) — LDB3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gludrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4YDP · 1.4 Å · ligand GLUTAMIC ACID (GLU). Experimental structure, not a prediction.
What the evidence adds up to
In 1997, a study of ten patients with hypertrophic obstructive cardiomyopathy temporarily occluded the first large septal branch of the left anterior descending coronary artery with a balloon catheter. During occlusion, the intraventricular gradient fell from a mean of 56.2 mmHg to 32.2 mmHg (p < 0.05), and after release it rose to 61.1 mmHg (p < 0.01). Regional ischaemia was confirmed by intracoronary electrocardiogram in all patients, and left ventricular end-diastolic pressure did not increase during the procedure. The authors concluded that this catheter-based ischaemia could form the basis for a new interventional therapy, but the study was a short-term physiological proof-of-concept in a very small sample, with no data on long-term outcomes, symptom relief, or survival.
Earlier reviews from 1987 and 1997 describe hypertrophic cardiomyopathy as a heterogeneous disease with no proven prognostic benefit from any therapy. A 1996 review states plainly that no therapies have been proven to improve prognosis and that there are few randomised trials of symptomatic treatment. The drugs available at that time were beta-blockers, calcium antagonists, and disopyramide, but the review does not report response rates or survival data from controlled trials. A 2001 case study mentions that early treatment of symptoms may improve haemodynamic benefits and prevent complications including sudden death, but this is a single-case observation, not a trial.
The 2024 guidelines note that scientific knowledge has improved significantly, with advances in imaging, genetics, and new medications addressing molecular mechanisms. However, the abstract does not name any specific drug, report any survival or response rates, or describe any completed trial. What remains missing are large, randomised, placebo-controlled trials with hard endpoints such as mortality or hospitalisation for heart failure. The catheter-based ischaemia concept from 1997 has not been shown in a controlled trial to improve prognosis. Patient stratification by genotype or phenotype is not yet validated for guiding therapy, and funding for definitive trials in this relatively uncommon disease remains limited.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1997 · 1011 citations
The Management of Hypertrophic Cardiomyopathy
AbstractHypertrophic cardiomyopathy is a complex cardiac disease with unique pathophysiologic characteristics and a great diversity of morphologic, functional, and clinical features.18 The heterogeneity of the disease is accentuated by the fact that it afflicts patients of all ages. During the past few years, technological developments in implantable defibrillators and pacemakers have provided new therapeutic options for patients with the disease.918 In addition, rapid advances in our knowledge of the molecular defects responsible for hypertrophic cardiomyopathy have deepened our understanding of the disorder and have suggested new approaches to the assessment of prognosis.1922 These recent developments, however, have . . .
New England Journal of Medicine · 1987 · 900 citations
Hypertrophic Cardiomyopathy
Abstract(First of Two Parts)HYPERTROPHIC cardiomyopathy has fascinated and often confused physicians for the quarter of a century since its recognition in the late 1950s.1 2 3 4 5 During this time, investigators have assembled an impressive array of observations spanning numerous aspects of the clinical identification, morphology, pathophysiology, and natural history of the disease. Much understanding has emerged from these investigative efforts; however, the intrinsic complexities of hypertrophic cardiomyopathy continue to create uncertainty and debate.Numerous studies have explored specific facets of hypertrophic cardiomyopathy, and several have comprehensively reviewed the broader aspects of its clinical profile and course, including the findings on physical . . .
Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: Studies to develop a new catheter-based concept of treatment
AbstractAIM: To develop a new catheter-based method of treatment in patients with hypertrophic obstructive cardiomyopathy. METHOD: Does abolition of the blood supply to the subaortic part of the septum lead to regional myocardial ischaemia and a decrease in the left ventricular outflow tract gradient? To find this out, in 10 consecutive patients the first larger septal branch of the left anterior descending coronary artery was temporarily occluded with conventional percutaneous transluminal coronary angioplasty. The intracoronary electrocardiogram was registered for objective verification of the intended ischaemia. The intraventricular pressure was measured at rest and at the post extrasystolic beat under programmed electrostimulation of the right ventricle. RESULTS: During occlusion, regional ischaemia was observed in all patients. Simultaneously, there was a significant reduction of the intraventricular gradient from 56.2 mmHg to 32.2 mmHg (P < 0.05) followed by an increase from 32.2 mmHg to 61.1 mmHg (P < 0.01) after release of occlusion of the septal branch. During ischaemia there was no increase in left ventricular end-diastolic pressure. CONCLUSION: We conclude that the results form the basis for a new catheter interventional therapy in hypertrophic obstructive cardiomyopathy.
Arquivos Brasileiros de Cardiologia · 2024 · 24 citations · open access
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024
Abstract1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...]
The Journal of Cardiovascular Nursing · 2001 · 2 citations
Hemodynamic Benefits of Treatment Modalities for Hypertrophic Cardiomyopathy: A Case Study
AbstractHypertrophic cardiomyopathy is a primary disease of the cardiac muscle characterized by a hypertrophied and nondilated left ventricle in the absence of other cardiac or systemic disease. The disorder occurs twice as often in men than in women and is relatively more common in young adults. Early treatment of symptoms may improve hemodynamic benefits and prevent complications, including sudden death. This case illustrates various treatment modalities used to manage symptoms and describes the challenges in effectively maintaining hemodynamic stability.
Medical Therapy for Symptomatic Patients with Hypertrophic Cardiomyopathy
AbstractHypertrophic cardiomyopathy is a relatively uncommon myocardial disease with a heterogeneous presentation and complex pathophysiology. The condition is often asymptomatic; when symptoms are present, however, they are usually multiple, and each has several potential mechanisms. No therapies have been proven to improve prognosis, and there are few randomized trials of symptomatic treatment. Within these limitations, an approach to assessing the symptomatic patient is presented. The major drugs available for symptomatic therapy, namely beta-blockers, calcium antagonists and disopyramide, are reviewed. An overall management plan and a step-by-step strategy for the treatment of the symptomatic patient are presented.
Journal of Contemporary Medical Practice · 2022 · 0 citations · open access
Progress in Clinical Treatment of Hypertrophic Cardiomyopathy with Traditional Chinese and Western Medicine
AbstractHypertrophic cardiomyopathy refers to cardiac hypertrophy caused by hypertension, aortic stenosis and other factors, with dyspnea, precardiac pain, fatigue, palpitations and other clinical manifestations, and ultimately can progress to heart failure; The clinical incidence of this disease is increasing year by year, and the complications are numerous, which seriously affect the prognosis. For the treatment of this disease, Chinese and western medicine have their own opinions, through combing the latest domestic and foreign relevant literature, systematically elaborated in recent years about the progress of Chinese and western medicine treatment of this disease, for the majority of doctors reference.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
